BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 21983363)

  • 1. Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice.
    Tobias J; Svennerholm AM; Carlin NI; Lebens M; Holmgren J
    Vaccine; 2011 Nov; 29(48):8863-9. PubMed ID: 21983363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria.
    Tobias J; Holmgren J; Hellman M; Nygren E; Lebens M; Svennerholm AM
    Vaccine; 2010 Oct; 28(43):6977-84. PubMed ID: 20728524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates.
    Tobias J; Svennerholm AM
    Appl Microbiol Biotechnol; 2012 Mar; 93(6):2291-300. PubMed ID: 22350259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae.
    Tobias J; Lebens M; Bölin I; Wiklund G; Svennerholm AM
    Vaccine; 2008 Feb; 26(6):743-52. PubMed ID: 18191006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccines.
    Tobias J; Svennerholm AM; Holmgren J; Lebens M
    Appl Microbiol Biotechnol; 2010 Jul; 87(4):1355-65. PubMed ID: 20405124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli.
    Qadri F; Ahmed T; Ahmed F; Bhuiyan MS; Mostofa MG; Cassels FJ; Helander A; Svennerholm AM
    Infect Immun; 2007 May; 75(5):2269-74. PubMed ID: 17296752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli.
    Lasaro MO; Luiz WB; Sbrogio-Almeida ME; Ferreira LC
    Vaccine; 2005 Mar; 23(19):2430-8. PubMed ID: 15752829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88.
    Remer KA; Bartrow M; Roeger B; Moll H; Sonnenborn U; Oelschlaeger TA
    Int J Med Microbiol; 2009 Nov; 299(7):467-78. PubMed ID: 19467927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.
    Jertborn M; Ahrén C; Svennerholm AM
    Clin Diagn Lab Immunol; 2001 Mar; 8(2):424-8. PubMed ID: 11238232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.
    Lásaro MO; Luiz WB; Sbrogio-Almeida ME; Nishimura LS; Guth BE; Ferreira LC
    Infect Immun; 2004 Nov; 72(11):6480-91. PubMed ID: 15501779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
    Byrd W; Boedeker EC
    Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
    Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ
    Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of mucosal immune response following oral administration of enterotoxigenic Escherichia coli fimbriae (CFA/I) entrapped in liposomes in conjunction with inactivated whole-cell Vibrio cholerae vaccine.
    Dima VF; Ionescu MD; Palade R; Balotescu C; Becheanu G; Dima SV
    Roum Arch Microbiol Immunol; 2001; 60(1):27-54. PubMed ID: 11850896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Co-expression of CFA/I and CS6 of Enterotoxigenic Escherichia coli ( ETEC ) in Shigella flexneri 2a T32 Derivative Strain FWL01].
    Zheng JP; Wang LC; Wang P; Luo G; Li SQ; Duan HQ; Huang CF; Zhang ZS
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Nov; 35(11):1005-10. PubMed ID: 14614538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Chimeric protein of CFA/I, CS6 subunits and LTB/STa toxoid protects immunized mice against enterotoxigenic Escherichia coli.
    Zeinalzadeh N; Salmanian AH; Goujani G; Amani J; Ahangari G; Akhavian A; Jafari M
    Microbiol Immunol; 2017 Jul; 61(7):272-279. PubMed ID: 28543534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization of BALB/c mice using enterotoxigenic Escherichia coli colonization factors CFA/I and CS6 administered with and without a mutant heat-labile enterotoxin.
    Byrd W; Cassels FJ
    Vaccine; 2003 May; 21(17-18):1884-93. PubMed ID: 12706673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of an attenuated strain oral vaccine candidate using a novel double selection platform in Escherichia coli.
    Liu W; Yuan C; Bao J; Guan W; Zhao Z; Li X; Tang J; Li D; Shi D
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):855-67. PubMed ID: 25301580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice.
    Oliveira AF; Cardoso SA; Almeida FB; de Oliveira LL; Pitondo-Silva A; Soares SG; Hanna ES
    Microbiol Immunol; 2012 Aug; 56(8):513-22. PubMed ID: 22671942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
    Lundgren A; Leach S; Tobias J; Carlin N; Gustafsson B; Jertborn M; Bourgeois L; Walker R; Holmgren J; Svennerholm AM
    Vaccine; 2013 Feb; 31(8):1163-70. PubMed ID: 23306362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.